HL237

HL237 is an investigational small molecule drug developed by Hanlim Pharmaceutical for the treatment of autoimmune disorders, primarily rheumatoid arthritis. It is classified as an antirheumatic and features a biguanide structure similar to that found in metformin. The mechanism of action involves inhibition of the STAT3 (Signal Transducer and Activator of Transcription 3) transcription factor, which plays a key role in immune regulation by inhibiting Th17 cells and activating Treg cells. By targeting STAT3, HL237 aims to modulate immune responses implicated in autoimmune diseases such as rheumatoid arthritis. Clinical development has reached Phase II trials for rheumatoid arthritis[1][2][3][4][5].